Acrivon Therapeutics announces FDA granted BDD for ACR-368
Acrivon Therapeutics (ACRV) announced the U.S. Food and Drug Administration, FDA, has granted Breakthrough Device designation, BDD, for the ...
Tectonic: Expansion Of TX45 Candidate Possible After Positive Interim Data
Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...
RenovoRx: From Clinical Promise To Commercial Reality And Trading At A Significant Discount
RenovoRx's innovative RenovoCath and TAMP platform show promising clinical data. Click here to read why RNXT stock presents ...
The Schall Law Firm Invites Shareholders With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation
LOS ANGELES, CA / ACCESS Newswire / February 5, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...
FDA recall for broccoli sold at Walmart
It could be contaminated with Listeria.
Amgen shares sink despite quarterly beat, FDA places obesity drug on clinical hold
Nearly 30 years after Matt Damon and Ben Affleck’s breakthrough movie, “Good Will Hunting,” they are sharing the screen again ...
Autolus Therapeutics Will Remain Depressed For A While
Autolus Therapeutics' obe-cel, branded Aucatzyl, is the first CAR-T therapy approved without a REMS, highlighting its safety and unique mechanism.
Hosted on MSN43m
Tonix Pharma Dominates Retail Biotech Buzz After 1-for-100 Reverse Split, Sentiment Turns Neutral Amid Volatility
Tonix Pharmaceuticals saw its shares swing wildly between gains and losses on Wednesday morning as they started to trade ...
Amgen says Phase 1 AMG 513 obesity study placed on clinical hold by FDA
Amgen (AMGN) provided updates on selected product and pipeline programs, including that a Phase 1 study of AMG 513 in people living with ...
EyePoint Pharmaceuticals stock sinks following clinical trial results
Investing.com -- Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ: EYPT) fell 21% today, diverging from the company's recent announcement of positive results from the Phase 2 VERONA clinical ...
TD Cowen maintains EyePoint stock Buy rating, $20 target
TD Cowen reiterated its Buy rating and $20.00 price target for EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT). This aligns with the broader analyst consensus, as InvestingPro data shows analyst targets ...
Big Pharma, Bigger Bargain: Why Merck Stock Is Too Cheap To Ignore (Upgrade)
Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...